Mizuho analyst Anthony Petrone raised the firm’s price target on Edwards Lifesciences to $102 from $95 and keeps a Buy rating on the shares. The analyst updated medtech and diagnostics price targets ahead of the Q2 reporting season.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW: